Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
Blanco Echevarría A, García Díaz JD, Caixas A, Plana Gil N, Rico Corral MÁ, Bridges I, Dhalwani N, Gatell Menchen S, Ray KK. Blanco Echevarría A, et al. Among authors: dhalwani n. Clin Investig Arterioscler. 2023 Nov-Dec;35(6):263-271. doi: 10.1016/j.arteri.2023.04.004. Epub 2023 May 24. Clin Investig Arterioscler. 2023. PMID: 37236829 Free article. English, Spanish.
Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.
Ray KK, Bruckert E, Peronne-Filardi P, Ebenbichler C, Vogt A, Bridges I, Sibartie M, Dhalwani N. Ray KK, et al. Among authors: dhalwani n. Atherosclerosis. 2023 Feb;366:14-21. doi: 10.1016/j.atherosclerosis.2023.01.002. Epub 2023 Jan 13. Atherosclerosis. 2023. PMID: 36696747 Free article.
Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
Blaha V, Margoczy R, Petrov I, Postadzhiyan A, Rašlová K, Rosolová H, Bridges I, Dhalwani NN, Zachlederova M, Ray KK. Blaha V, et al. Among authors: dhalwani nn. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484231172847. doi: 10.1177/10742484231172847. J Cardiovasc Pharmacol Ther. 2023. PMID: 37218974 Free article.
Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study.
Blaha V, Margoczy R, Petrov I, Postadzhiyan A, Raslova K, Rosolova H, Bridges I, Dhalwani NN, Zachlederova M, Ray KK. Blaha V, et al. Among authors: dhalwani nn. Eur Cardiol. 2023 Apr 25;18:e36. doi: 10.15420/ecr.2023.18.PO19. eCollection 2023. Eur Cardiol. 2023. PMID: 37405342 Free PMC article. Review. No abstract available.
Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study.
Vlachopoulos C, Massia D, Kochiadakis G, Kolovou G, Patsilinakos S, Bridges I, Sibartie M, Dhalwani NN, Liberopoulos E, Ray KK. Vlachopoulos C, et al. Among authors: dhalwani nn. Hellenic J Cardiol. 2023 Nov-Dec;74:74-76. doi: 10.1016/j.hjc.2023.09.003. Epub 2023 Sep 18. Hellenic J Cardiol. 2023. PMID: 37730147 Free article. No abstract available.
Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline.
Alanaeme CJ, Bittner V, Brown TM, Colantonio LD, Dhalwani N, Jones J, Kalich B, Exter J, Jackson EA, Levitan EB, Poudel B, Wang Z, Woodward M, Muntner P, Rosenson RS. Alanaeme CJ, et al. Among authors: dhalwani n. Am Heart J Plus. 2022 Sep;21:100201. doi: 10.1016/j.ahjo.2022.100201. Epub 2022 Aug 27. Am Heart J Plus. 2022. PMID: 37168932 Free PMC article.
Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction.
Sakhuja S, Bittner VA, Brown TM, Farkouh ME, Levitan EB, Safford MM, Woodward M, Chen L, Sun R, Dhalwani N, Jones J, Kalich B, Exter J, Muntner P, Rosenson RS, Colantonio LD. Sakhuja S, et al. Among authors: dhalwani n. Cardiovasc Drugs Ther. 2024 Oct;38(5):937-945. doi: 10.1007/s10557-023-07452-1. Epub 2023 Apr 13. Cardiovasc Drugs Ther. 2024. PMID: 37052867
Achievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry.
Navar AM, Shah NP, Shrader P, Thomas LE, Ahmad Z, Allred C, Chamberlain AM, Chrischilles EA, Dhalwani N, Effron MB, Hayek S, Jones LK, Kalich B, Shapiro MD, Wójcik C, Peterson ED. Navar AM, et al. Among authors: dhalwani n. Am Heart J. 2024 Jul 6:S0002-8703(24)00165-0. doi: 10.1016/j.ahj.2024.06.012. Online ahead of print. Am Heart J. 2024. PMID: 38972336
60 results